Selvita S.A. (SLV) - Total Assets
Based on the latest financial reports, Selvita S.A. (SLV) holds total assets worth zł597.77 Million PLN (≈ $164.52 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SLV total equity for net asset value and shareholders' equity analysis.
Selvita S.A. - Total Assets Trend (2015–2025)
This chart illustrates how Selvita S.A.'s total assets have evolved over time, based on quarterly financial data.
Selvita S.A. - Asset Composition Analysis
Current Asset Composition (December 2025)
Selvita S.A.'s total assets of zł597.77 Million consist of 21.2% current assets and 78.8% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 4.1% |
| Accounts Receivable | zł67.77 Million | 11.3% |
| Inventory | zł7.78 Million | 1.3% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł24.45 Million | 4.1% |
| Goodwill | zł88.87 Million | 14.9% |
Asset Composition Trend (2015–2025)
This chart illustrates how Selvita S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Selvita S.A. market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Selvita S.A.'s current assets represent 21.2% of total assets in 2025, a decrease from 74.4% in 2015.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, down from 44.2% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 3.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 14.9% of total assets.
Selvita S.A. Competitors by Total Assets
Key competitors of Selvita S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs31.46 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Check-Cap Ltd.
NASDAQ:MBAI
|
USA | $7.49 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Selvita S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.04 | 0.61 | 2.05 |
| Quick Ratio | 0.98 | 0.57 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł5.20 Million | zł-81.03 Million | zł71.91 Million |
Selvita S.A. - Advanced Valuation Insights
This section examines the relationship between Selvita S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.80 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -6.9% |
| Total Assets | zł597.77 Million |
| Market Capitalization | $155.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Selvita S.A.'s assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Selvita S.A.'s assets decreased by 6.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Selvita S.A. (2015–2025)
The table below shows the annual total assets of Selvita S.A. from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł597.77 Million ≈ $164.52 Million |
-6.90% |
| 2024-12-31 | zł642.09 Million ≈ $176.71 Million |
+0.92% |
| 2023-12-31 | zł636.26 Million ≈ $175.11 Million |
+8.78% |
| 2022-12-31 | zł584.91 Million ≈ $160.98 Million |
+25.36% |
| 2021-12-31 | zł466.59 Million ≈ $128.41 Million |
+113.25% |
| 2020-12-31 | zł218.80 Million ≈ $60.22 Million |
+140.73% |
| 2019-12-31 | zł90.89 Million ≈ $25.01 Million |
+25.22% |
| 2018-12-31 | zł72.58 Million ≈ $19.98 Million |
+51.41% |
| 2017-12-31 | zł47.94 Million ≈ $13.19 Million |
-46.21% |
| 2016-12-31 | zł89.12 Million ≈ $24.53 Million |
+36.60% |
| 2015-12-31 | zł65.24 Million ≈ $17.96 Million |
-- |
About Selvita S.A.
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libr… Read more